# EDGAR Filing Document

**Accession Number:** 0001681682
**File Stem:** 0000898432-25-000936
**Filing Date:** 2025-11
**Character Count:** 8740
**Document Hash:** a79c81519a4c342709e55d640e7c4325
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000898432-25-000936.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0000898432-25-000936

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ENDRA Life Sciences Inc.
- **CENTRAL INDEX KEY:** 0001681682
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 260579295
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-90044
- **FILM NUMBER:** 251530804

**BUSINESS ADDRESS:**
- **STREET 1:** 3600 GREEN COURT
- **STREET 2:** SUITE 350
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48105
- **BUSINESS PHONE:** 734-335-0468

**MAIL ADDRESS:**
- **STREET 1:** 3600 GREEN COURT
- **STREET 2:** SUITE 350
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Endra Inc.
- **DATE OF NAME CHANGE:** 20160805
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DIGIANDOMENICO ANTHONY
- **CENTRAL INDEX KEY:** 0001083544
- **STANDARD INDUSTRIAL CLASSIFICATION:** UNKNOWN SIC - 0000 [0000]

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 3600 GREEN COURT, SUITE 350
- **CITY:** ANN ARBOR
- **STATE:** MI
- **ZIP:** 48105

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**ENDRA Life Sciences Inc.**

*(Name of Issuer)*

**Common Stock**

*(Title of Class of Securities)*

**29273B401**

*(CUSIP Number)*

**Alexander Tokman**<br>c/o ENDRA Life Sciences Inc.<br>3600 Green Court, Suite 350<br>Ann Arbor MI 48105<br>734-335-0468

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**10/15/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **29273B401** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Anthony DiGiandomenico** | Name of reporting person<br>**Anthony DiGiandomenico** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**121622.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**121622.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**121622.00** | Aggregate amount beneficially owned by each reporting person<br>**121622.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[x] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.99%** | Percent of class represented by amount in Row (11)<br>**9.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** NOTE FOR ROWS 7 and 9:  Consists of (i) 70,881 shares of common stock, (ii) 9 shares of common stock issuable upon the exercise of options and (iii) warrants to purchase up to 50,800 shares of common stock. The totals reported exclude warrants to purchase up to 90,844 shares of common stock. The warrants held by Mr. DiGiandomenico are subject to a beneficial ownership limitation of 9.99%, and such limitation restricts Mr. DiGiandomenico from exercising that portion of the warrants that would result in Mr. DiGiandomenico and his affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The beneficial ownership of Mr. DiGiandomenico reported herein reflects this limitation.

NOTE FOR ROW 13:  Based on the 1,166,441 shares of common stock outstanding as of November 14, 2025. The number of shares deemed outstanding in accordance with Rule 13d-3(d)(i) under the Exchange Act (taking into account the number of shares issuable upon the exercise of options warrants held by Mr. DiGiandomenico that are reported herein, as required by that Rule) is 1,217,250.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock

**(b) Name of Issuer:**
ENDRA Life Sciences Inc.

**(c) Address of Issuer's Principal Executive Offices:**
3600 Green Court, Suite 350, Ann Arbor, MI, 48105

This Schedule 13D relates to the shares of common stock, par value $0.0001 (the "Common Stock") of ENDRA Life Sciences Inc. (the "Issuer"). The principal executive offices of the Issuer are located at 3600 Green Court, Suite 350 Ann Arbor, MI.

**Item 4. Purpose of Transaction**

The Reporting Person is a member of the Board of Directors of the Issuer. In such capacity, he may engage in communications with the Board of Directors of the Issuer, members of management of the Issuer, other shareholders of the Issuer, financial and legal advisers and other parties regarding the Issuer, including but not limited to its operations, governance and control. In addition, in his capacity as a member of the Board, the Reporting Person may have influence over the corporate activities of the Issuer, including activities which may relate to items described in subparagraphs (a) through (j) of the instructions to Item 4 of Schedule 13D.

Except as set forth herein, the Reporting Person does not have any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Person may, at any time and from time to time, review or reconsider his positions and/or change his purpose and/or formulate plans or proposals with respect thereto.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person beneficially owns an aggregate of 121,622 shares of the Issuer's Common Stock. Such amount represents 9.99% of the outstanding shares of Common Stock based on the 1,166,441 shares of Common Stock outstanding as of November 14, 2025. The number of shares deemed outstanding in accordance with Rule 13d-3(d)(i) under the Exchange Act (taking into account the number of Shares issuable upon the exercise of options and warrants held by the Reporting Person that are reported herein, as required by that Rule) is 1,217,250.

**(b)**
The Reporting Person has the sole power to vote or direct the vote of 121,622 Common Shares; has the shared power to vote or direct the vote of no Common Shares; has the sole power to dispose or direct the disposition of 121,622 Common Shares; and has the shared power to dispose or direct the disposition of no Common Shares.

**(c)**
On October 10, 2025, the Reporting Person purchased 70,822 shares of Common Stock and 141,644 warrants to purchase Common Stock pursuant to a Securities Purchase Agreement with the Issuer. The purchase price per share of Common Stock and accompanying warrant was $7.06.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

There are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Person and any other person with respect to any securities of the Issuer.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Anthony DiGiandomenico

**Signature:** /s/ Anthony DiGiandomenico

**Name/Title:** Anthony DiGiandomenico

**Date:** 11/26/2025